Live Attenuated Influenza Vaccination Prior To Age 3 Years and Subsequent Development of Asthma: A 14-Year Follow-Up Study.

about

Live Attenuated Influenza Vaccination Prior To Age 3 Years and Subsequent Development of Asthma: A 14-Year Follow-Up Study.

Item

http://www.wikidata.org/entity/Q50071104

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Live Attenuated Influenza Vacc ...... ma: A 14-Year Follow-Up Study.

@en

Live Attenuated Influenza Vacc ...... ma: A 14-Year Follow-Up Study.

@nl

type

Item

label

Live Attenuated Influenza Vacc ...... ma: A 14-Year Follow-Up Study.

@en

Live Attenuated Influenza Vacc ...... ma: A 14-Year Follow-Up Study.

@nl

prefLabel

Live Attenuated Influenza Vacc ...... ma: A 14-Year Follow-Up Study.

@en

Live Attenuated Influenza Vacc ...... ma: A 14-Year Follow-Up Study.

@nl

P1476

Live Attenuated Influenza Vacc ...... ma: A 14-Year Follow-Up Study.

@en

P2093

Bruce Fireman

http://www.w3.org/2001/XMLSchema#string

John Hansen

http://www.w3.org/2001/XMLSchema#string

Justin R Ortiz

http://www.w3.org/2001/XMLSchema#string

Ned Lewis

http://www.w3.org/2001/XMLSchema#string

Roger P Baxter

http://www.w3.org/2001/XMLSchema#string

P2860

A global review of national influenza immunization policies: Analysis of the 2014 WHO/UNICEF Joint Reporting Form on immunization

WHO initiative to increase global and equitable access to influenza vaccine in the event of a pandemic: supporting developing country production capacity through technology transfer.

Efficacy of a Russian-backbone live attenuated influenza vaccine among young children in Bangladesh: a randomised, double-blind, placebo-controlled trial

Role of viral respiratory infections in asthma and asthma exacerbations

Diabetes and asthma case identification, validation, and representativeness when using electronic health data to construct registries for comparative effectiveness and epidemiologic research.

Live attenuated influenza vaccine, trivalent, is safe in healthy children 18 months to 4 years, 5 to 9 years, and 10 to 18 years of age in a community-based, nonrandomized, open-label trial.

Efficacy of a Russian-backbone live attenuated influenza vaccine among children in Senegal: a randomised, double-blind, placebo-controlled trial.

Global burden of respiratory infections due to seasonal influenza in young children: a systematic review and meta-analysis.

Safety of Russian-backbone seasonal trivalent, live-attenuated influenza vaccine in a phase II randomized placebo-controlled clinical trial among children in urban Bangladesh.

Safety and efficacy of live attenuated influenza vaccine in children 2-7 years of age.

P304

383-386

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1097/INF.0000000000001783

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Nicola P Klein

P577

2018-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28914750

http://www.w3.org/2001/XMLSchema#string

P921

attenuated vaccine

P932

5847407

http://www.w3.org/2001/XMLSchema#string